# Luwei

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/luwei

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Website: www.biomanifold.com/
- Latest round: Series A (Jan 23, 2026)
- Investors on record: 1

## About

Luwei Biotechnology Co., Ltd., based in Shenzhen, China, specializes in the development and manufacturing of advanced immunodiagnostic and molecular diagnostic products that aid in disease detection and monitoring.Founded in 2021, Shenzhen Luwei Biotechnology Co., Ltd. focuses on creating innovative diagnostic solutions. The company has completed one significant deal as of January 2026. There is no mention of previous pivots or subsidiaries. The founder's history is not disclosed, and there are no references to any prior companies.Shenzhen Luwei Biotechnology Co., Ltd. specializes in the research, development, and manufacturing of immunodiagnostic and molecular diagnostic products. The company’s core offerings include the NephroPlex™ assay kit, which utilizes proprietary molecular probe technology to detect polyclonal IgA immune complexes in peripheral blood—an indicator primarily associated with the pathogenesis of IgA nephropathy. This innovative product has been validated as a reliable marker for assessing immune activity in patients with IgA nephropathy, aiding in diagnosis, monitoring, and treatment planning. Additionally, the company addresses cancer recurrence risk assessment through RNA testing, with a notable focus on breast and lung cancers. These diagnostic tools are aimed at healthcare providers, patients, and pharmaceutical companies, facilitating third-party medical testing laboratory services. The primary geographical markets served by Luwei Biotechnology include the Chinese healthcare sector, with potential outreach to broader Asian markets.Shenzhen Luwei Biotechnology generates revenue through the sale of diagnostic products and services, structured primarily as B2B transactions with healthcare institutions, laboratories, and pharmaceutical companies. The firm’s flagship NephroPlex™ assay kit and other RNA testing services for breast and lung cancer are offered directly to clinical labs and hospitals, which may implement these diagnostics in their treatment protocols. Revenue transactions generally involve the purchase of testing kits, which are priced based on their specific diagnostic capabilities and associated services. Additionally, partnerships with healthcare providers may facilitate bulk purchases and long-term contracts, enhancing the firm's revenue streams. The company’s focus on precision medicine positions it favorably within the growing market for advanced diagnostic solutions in oncology and nephrology.In January 2026, Luwei raised an undisclosed amount of SERIES A+ funding led by new investor Gantou Capital. The company intends to use this funding to support the research and development of immunodiagnostic products, thus accelerating its expansion in both the Chinese and global markets.

## Funding rounds

- Series A, Jan 23, 2026 — Gantou Capital

## Investors

- Gantou Capital (https://capitalatlas.ai/funds/gantou-capital) — Series A